tirzepatide maximum weight loss surmount trials SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide dose chart: complete dosing

doi: 10.2337/dc19-1562

Despite these challenges, the consistent and robust benefits observed in this cohort reinforce tirzepatide's translational potential (Aronne et al., 2024[3]

Study looks into which weight-loss drug makes you lose the most muscle Exercise during treatment is essential with both drugs, researchers say Bookmark CommentsGo to comments A new study suggests that Eli Lillys GLP-1 drug tirzepatide, marketed as Zepbound and Mounjaro, leads to greater overall weight loss than Novo Nordisks semaglutide, sold as Wegovy and Ozempic

Due to its dual receptor activation mechanism, Tirzepitide tends to offer more significant weight loss when compared to Semaglutide